Palisade Bio and Newsoara’s LB1148 Receive NMPA’s Clearance to Initiate P-III Trial to Improve Bowel Function After Abdominal Surgery
Shots:
- NMPA has granted clearance to initiate the P-III trial evaluating the safety and efficacy of LB1148 in adult patients for accelerated return of bowel function undergoing bowel/abdominal surgery
- In the P-II trial for GI surgery, LB1148 showed a significant effect in accelerating the return of bowel function in patients undergoes elective bowel resection surgery & has a favorable safety and tolerability profile
- Under the terms of the agreement with Palisade Bio, Newsoara is responsible to fund the P-III development in China. In return, Palisade Bio will eligible to receive additional fees upon the achievement of regulatory and commercial milestones along with royalty on net sales of LB1148 in greater China
Ref: Globenewswire | Image: Palisade
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
